Cargando…
Induction of long-term tolerance to a specific antigen using anti-CD3 lipid nanoparticles following gene therapy
Development of factor VIII (FVIII) inhibitors is a serious complication in the treatment of hemophilia A (HemA) patients. In clinical trials, anti-CD3 antibody therapy effectively modulates the immune response of allograft rejection or autoimmune diseases without eliciting major adverse effects. In...
Autores principales: | Chen, Chun-Yu, Vander Kooi, Amber, Cavedon, Alex, Cai, Xiaohe, Hoggatt, Jonathan, Martini, Paolo G.V., Miao, Carol H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Gene & Cell Therapy
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10618827/ https://www.ncbi.nlm.nih.gov/pubmed/37920545 http://dx.doi.org/10.1016/j.omtn.2023.102043 |
Ejemplares similares
-
Treatment of Hemophilia A Using Factor VIII Messenger RNA Lipid Nanoparticles
por: Chen, Chun-Yu, et al.
Publicado: (2020) -
Nanoparticles for the Induction of Antigen-Specific Immunological Tolerance
por: Kishimoto, Takashi Kei, et al.
Publicado: (2018) -
Induction of antigen-specific immune tolerance using biodegradable nanoparticles containing antigen and dexamethasone
por: Kim, Sang-Hyun, et al.
Publicado: (2019) -
Influence of N-glycosylation in the A and C domains on the immunogenicity of factor VIII
por: Vander Kooi, Amber, et al.
Publicado: (2022) -
Induction of Antigen-Specific Tolerance in Autoimmune Diabetes with Nanoparticles Containing Hybrid Insulin Peptides
por: DiLisio, James E., et al.
Publicado: (2021)